Literature DB >> 15954490

Duration of virus shedding after trivalent intranasal live attenuated influenza vaccination in adults.

Thomas R Talbot1, Deidre D Crocker, Jody Peters, Jennifer K Doersam, Mine R Ikizler, Edith Sannella, Peter E Wright, Kathryn M Edwards.   

Abstract

OBJECTIVE: To characterize the probability and duration of viral shedding among adults given trivalent live attenuated influenza vaccine (LAIV).
DESIGN: Prospective surveillance study.
METHODS: Nasal wash samples were collected from adult volunteers at baseline and on days 3, 7, and 10 and between days 17 and 21 following intranasal LAIV vaccination. The presence, titer, and identification of each specific strain of influenza virus shed were determined by standard methodology.
RESULTS: Twenty subjects received LAIV. No samples were positive for influenza virus at baseline. After LAIV vaccination, influenza virus was recovered from 10 of 20 vaccinees on day 3, from 1 of 18 vaccinees on day 7, and from none of the samples on days 10 or 17 through 21. Vaccinees who shed vaccine virus were significantly younger than those who did not (mean age, 26.4 vs 38.6 years; P < .01). Although the presence of specific mucosal immunoglobulin A to influenza B was associated with significantly less shedding of influenza B after vaccination (P = .02), associations of shedding with other measures of immunity were not detected.
CONCLUSION: The duration of shedding of vaccine virus after LAIV in adults i s limited and may be associatedwith an individual's prior influenza vaccination history.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15954490     DOI: 10.1086/502574

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  11 in total

Review 1.  Influenza vaccines: from surveillance through production to protection.

Authors:  Pritish K Tosh; Robert M Jacobson; Gregory A Poland
Journal:  Mayo Clin Proc       Date:  2010-01-29       Impact factor: 7.616

2.  Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.

Authors:  Marcie Tomblyn; Tom Chiller; Hermann Einsele; Ronald Gress; Kent Sepkowitz; Jan Storek; John R Wingard; Jo-Anne H Young; Michael J Boeckh; Michael A Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2009-10       Impact factor: 5.742

Review 3.  Live attenuated influenza vaccine (FluMist®; Fluenz™): a review of its use in the prevention of seasonal influenza in children and adults.

Authors:  Natalie J Carter; Monique P Curran
Journal:  Drugs       Date:  2011-08-20       Impact factor: 9.546

4.  Transocular entry of seasonal influenza-attenuated virus aerosols and the efficacy of n95 respirators, surgical masks, and eye protection in humans.

Authors:  Werner E Bischoff; Tanya Reid; Gregory B Russell; Timothy R Peters
Journal:  J Infect Dis       Date:  2011-07-15       Impact factor: 5.226

5.  Recommendations on the use of live, attenuated influenza vaccine (FluMist®): Supplemental Statement on Seasonal Influenza Vaccine for 2011-2012 An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).

Authors: 
Journal:  Can Commun Dis Rep       Date:  2011-11-30

6.  Pre-existing influenza-specific nasal IgA or nasal viral infection does not affect live attenuated influenza vaccine immunogenicity in children.

Authors:  M E Cole; R Kundu; A F Abdulla; N Andrews; K Hoschler; J Southern; D Jackson; E Miller; M Zambon; P J Turner; J S Tregoning
Journal:  Clin Exp Immunol       Date:  2021-01-13       Impact factor: 5.732

7.  Influenza Virus Detection Following Administration of Live-Attenuated Intranasal Influenza Vaccine in Children With Cystic Fibrosis and Their Healthy Siblings.

Authors:  Constantina Boikos; Lawrence Joseph; Christine Martineau; Jesse Papenburg; David Scheifele; Larry C Lands; Gaston De Serres; Mark Chilvers; Caroline Quach
Journal:  Open Forum Infect Dis       Date:  2016-08-30       Impact factor: 3.835

Review 8.  Novel Approaches for The Development of Live Attenuated Influenza Vaccines.

Authors:  Pilar Blanco-Lobo; Aitor Nogales; Laura Rodríguez; Luis Martínez-Sobrido
Journal:  Viruses       Date:  2019-02-22       Impact factor: 5.048

9.  Diagnostic discrimination of live attenuated influenza vaccine strains and community-acquired pathogenic strains in clinical samples.

Authors:  Nikki E Freed; Christopher A Myers; Kevin L Russell; Elizabeth A Walter; Marina Irvine; Robert G Coon; David Metzgar
Journal:  Mol Cell Probes       Date:  2006-09-08       Impact factor: 2.365

10.  Comparative study of influenza virus replication in MDCK cells and in primary cells derived from adenoids and airway epithelium.

Authors:  Natalia A Ilyushina; Mine R Ikizler; Yoshihiro Kawaoka; Larisa G Rudenko; John J Treanor; Kanta Subbarao; Peter F Wright
Journal:  J Virol       Date:  2012-08-22       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.